Overview

Topotecan Pharmacokinetic Characterization Study

Status:
Completed

Trial end date:
2007-08-09

Target enrollment:

Participant gender:

Summary

A multi-center, open label, single dose Phase I pharmacokinetic (PK) characterization of weekly IV (intravenous) topotecan given at 4mg/m2. 15 patients will be evaluated.

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Topotecan